Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Oncology Biomarker Database Includes Cancer Companion Diagnostic Pathway

By LabMedica International staff writers
Posted on 29 Dec 2011
A comprehensive cancer biomarker database has been launched that can help in finding new diagnostic, prognostic, and companion diagnostic biomarkers.

The database includes cancer companion-diagnostics biomarker pathway maps. More...
It contains more than 8,500 discovery phase, preclinical, or clinical cancer biomarkers that were identified or validated using patient derived samples.

Sciclips (Madison, MI, USA) launched the database, which covers a wide variety of biomarkers such as blood cancer biomarkers (peripheral blood, plasma, serum etc), tumor biomarkers, urinary cancer biomarkers, fecal cancer biomarkers, saliva cancer biomarkers, breath cancer biomarkers, etc.

More than 100 types of cancer are included in the cancer biomarker database. For each cancer type, the biomarkers are classified into diagnostic biomarkers; for the diagnostics application, disease predictive/risk assessment biomarkers; for predicting the risk or genetic susceptibility in developing cancer; drug efficacy/response biomarkers; biomarkers for studying the efficacy of anticancer drug treatments, including predictive biomarkers and prognostic biomarkers; and for determining the clinical outcome in cancer patients.

The types of cancer biomarkers include protein biomarkers, miRNA biomarkers, single-nucleotide polymorphism (SNP) biomarkers, gene expression biomarkers, epigenetic biomarkers, and metabolomic biomarkers.

With the growing trend of personalized healthcare concept and advance in biomarker research, there is a need for development of innovative personalized cancer drugs with companion biomarker assays to identify the most appropriate cancer patient, tumor type, and disease state.

Patient/sample details, experimental results, observations, biological and molecular functional analysis, biological process analysis, protein-protein interaction networks of each biomarker are listed in the database.

The pathway maps will help to identify new anticancer drug predictive and response biomarkers, for the discovery of new drug targets with improved efficacy or targeted therapy to overcome side effects, patient stratification, developing personalized strategies for monitoring cancer progression, treatment, diagnosis, and prognosis.

Related Links:

Sciclips




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.